Blood Pressure

Essential Hypertension and Vascular Remodeling

Please note: This summary is a concise interpretation of the original article; please refer to the source for the full context and details.

Meta‑analysis of RCTs (TGD + Nifedipine)

A 2020 updated meta‑analysis of randomized controlled trials assessed Tianma Gouteng Decoction (TGD) combined with nifedipine versus nifedipine alone for essential hypertension.

• Across included RCTs, modified TGD + nifedipine significantly reduced:

  • Systolic BP by about 6.8 mmHg and

  • Diastolic BP by about 2.35 mmHg beyond nifedipine alone,
    with low heterogeneity.

• Combination therapy also improved TCM symptom scores (dizziness, headache, tinnitus) more than nifedipine alone.

• No serious adverse events attributable to TGD were reported; overall safety was judged acceptable, but trial quality (blinding, allocation concealment) was often suboptimal.

Cerebral Infarction and Neuroprotection

Please note: This summary is a concise interpretation of the original article; please refer to the source for the full context and details.

A 2021 Frontiers in Pharmacology network‑pharmacology + experimental study explored Tianma Gouteng (TMGT) for cerebral infarction (CI).

• TMGT significantly reduced neuronal damage and neuroinflammation in:

  • Oxygen‑glucose deprivation (OGD) neuron models and

  • LPS‑induced inflammatory models.

• TMGT decreased the release of IL‑6, IL‑1β, and TNF‑α in a dose‑dependent manner.

• Mechanistic pathway: TMGT increased PPARγ expression and downregulated p‑P65, p‑IκBα, and HIF‑1α, indicating inhibition of the HIF‑1α/PPARγ/NF‑κB pathway as a key neuroprotective mechanism.

• Molecular docking pointed to quercetin as a core TMGT constituent with strong binding to targets relevant to neuroinflammation and neuronal survival.

Clinically, formulations of Tian Ma Gou Teng are widely used for post‑stroke dizziness, hemiplegia, tremor, and neuropathic sequelae; these mechanistic data support that practice.

Preeclampsia / Pregnancy‑Related Hypertension (preclinical)

Please note: This summary is a concise interpretation of the original article; please refer to the source for the full context and details.

A 2022 study showed that TGD exerts pregnancy‑protective effects in preeclampsia‑related models.

• In preeclamptic placental explants and TEV‑1 trophoblast‑derived cells, TGD:

  • Downregulated H₂O₂‑induced ROS levels, and

  • Upregulated NO production suppressed by oxidative stress.

• This suggests TGD regulates oxidative stress and NO balance in human extravillous trophoblast cells, possibly explaining beneficial effects in pregnancy‑related hypertensive disorders; translation to clinical use still requires caution and human data.

Parkinson’s Disease and Movement Disorders (mechanistic)

Please note: This summary is a concise interpretation of the original article; please refer to the source for the full context and details.

A 2023 network‑pharmacology study investigated Tianma Gouteng Decoction (TMGTD) in Parkinson’s disease (PD).

• Key active components: quercetin, kaempferol, palmitic acid.

• Major putative targets: ALB, GAPDH, AKT1, and pathways linked to:

  • Neurotransmitter receptor activity,

  • G‑protein coupled receptors,

  • Dopamine receptor signaling.

• GO/KEGG analyses indicate TMGT’s PD effects are closely related to dopaminergic neurotransmission and neuroprotection, supporting its traditional use for tremors and early Parkinsonian symptoms.